Business
EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025
Eisai Inc. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (Aβ) protofibril* antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI®), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toron
About this update from Eisai Co., Ltd.
[{"type":"text","content":"Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid, and a subcutaneous form of lecanemab for continued treatment of AD","length":267,"tagName":"p","attribs":{}},{"type":"text","content":"AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition ","length":149,"tagName":"p","attribs":{}},{"type":"text","content":"NUTLEY, N.J., July 21, 2025 /PRNewswire/ -- Eisai Inc. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (Aβ) protofibril* antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI®), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27 - 31. Eisai will present 21 oral presentations, 24 posters, three (3) symposia and two (2) lecanemab product theaters.","length":715,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Eisai Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Eisai Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":270,"url":"https://media.zenfs.com/en/prnewswire.com/700c877d19b6c71682541aaa54eb34cb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9Joz3h2FdUIAcnZzvGHF3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/700c877d19b6c71682541aaa54eb34cb","width":400,"height":270}},"href":"https://mma.prnewswire.com/media/2704698/Eisai_Inc_Logo_New.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Key Oral Lecanemab Presentations","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Four-year Data: On Wednesday, July 30, as part of the "Developing Topics Session: Innovative Therapeutic Approaches" (8:00 – 8:45 AM EDT), initial four-year findings will be presented on lecanemab from the Phase 3 Clarity AD Open-Label Extension in Early Alzheimer's Disease trial....